FTC Acts to Stop Deceptive COVID-19 Advertising Claims by California’s Precision Patient Outcomes, Inc.

In its complaint, the FTC is seeking to permanently stop the company and its CEO from using deceptive treatment or prevention claims with no supporting scientific evidence to sell their dietary supplement.

Metadata
Provider: 
FTCFTC
URL: 
https://www.ftc.gov/news-events/news/press-releases/2022/11/ftc-acts-stop-deceptive-covid-19-advertising-claims-californias-precision-patient-outcomes-inc-0https://www.ftc.gov/news-events/news/press-releases/2022/11/ftc-acts-stop-deceptive-covid-19-advertising-claims-californias-precision-patient-outcomes-inc-0
Retrieved on: 
Friday, November 25, 2022
Information
Tags: 
Consumer protection, Federal Trade Commission, FTC, Douglas v. U.S. District Court ex rel Talk America, Advertising, Marketing, Commission, District court, News, Zinc, Federal Trade Commission Act of 1914, Social media, Science, CEO, COVID, Blog, Vitamin, COVID-19, Fraud, Complaint, Health, Dietary supplement, Pharmaceutical industry, TikTok, Facebook
Geotags: 
CALIFORNIA
Summary
Key Points: 
  • In its complaint, the FTC is seeking to permanently stop the company and its CEO from using deceptive treatment or prevention claims with no supporting scientific evidence to sell their dietary supplement.
  • The FTC alleges that these practices violate the FTC Act and the COVID-19 Consumer Protection Act.
  • Lewis, the companys co-founder and CEO, formulated the product and is in direct control of Precision Patient Outcomes business operations.
  • Follow the FTC on social media, read consumer alerts and the business blog, and sign up to get the latest FTC news and alerts.
Copyright: 
2022 FTC. All Rights Reserved.